Response to "Reassessing Claims of Non-inferiority of Daptomycin".
Publication
, Journal Article
Shaw, GJ; Lindsell, CJ
Published in: J Emerg Med
April 2017
Duke Scholars
Published In
J Emerg Med
DOI
ISSN
0736-4679
Publication Date
April 2017
Volume
52
Issue
4
Start / End Page
584 / 585
Location
United States
Related Subject Headings
- Staphylococcus aureus
- Humans
- Emergency & Critical Care Medicine
- Daptomycin
- Anti-Bacterial Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shaw, G. J., & Lindsell, C. J. (2017). Response to "Reassessing Claims of Non-inferiority of Daptomycin". J Emerg Med, 52(4), 584–585. https://doi.org/10.1016/j.jemermed.2016.10.048
Shaw, George J., and Christopher J. Lindsell. “Response to "Reassessing Claims of Non-inferiority of Daptomycin".” J Emerg Med 52, no. 4 (April 2017): 584–85. https://doi.org/10.1016/j.jemermed.2016.10.048.
Shaw GJ, Lindsell CJ. Response to "Reassessing Claims of Non-inferiority of Daptomycin". J Emerg Med. 2017 Apr;52(4):584–5.
Shaw, George J., and Christopher J. Lindsell. “Response to "Reassessing Claims of Non-inferiority of Daptomycin".” J Emerg Med, vol. 52, no. 4, Apr. 2017, pp. 584–85. Pubmed, doi:10.1016/j.jemermed.2016.10.048.
Shaw GJ, Lindsell CJ. Response to "Reassessing Claims of Non-inferiority of Daptomycin". J Emerg Med. 2017 Apr;52(4):584–585.
Published In
J Emerg Med
DOI
ISSN
0736-4679
Publication Date
April 2017
Volume
52
Issue
4
Start / End Page
584 / 585
Location
United States
Related Subject Headings
- Staphylococcus aureus
- Humans
- Emergency & Critical Care Medicine
- Daptomycin
- Anti-Bacterial Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences